Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

Benzinga · 3d ago
Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $83 to $110.